BLCO or DHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
BLCO vs. HQY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation - Analyst/Investor Day Transcript
Bausch + Lomb Corporation ( BLCO ) Bausch + Lomb Corporation - Analyst/Investor Day November 13, 2025 8:30 AM EST Company Participants Brenton Saunders - CEO & Chairman of the Board Osama Eldessouky - Executive VP & CFO Yehia Hashad - Executive VP of Research & Development and Chief Medical officer John Ferris - President of Consumer Mayssa Attar Andrew Stewart - President of Global Pharmaceuticals & International Consumer Yang Yang - President of Vision Care Bryan Reed Luc Bonnefoy - President of Surgical Kelly Swaim Cathleen McCabe Eric Donnenfeld Mark Schaeffer Lejla Vajzovic Conference Call Participants William Trattler Lejla Vajzovic Eric Donnenfeld Mark Schaeffer Patrick Wood - Morgan Stanley, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Kevin Joaquin Joanne Wuensch - Citigroup Inc., Research Division Young Li - Jefferies LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Presentation Brenton Saunders CEO & Chairman of the Board So good morning, everyone. Thank you for joining us here.
Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript
Bausch + Lomb Corporation ( BLCO ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants George Gadkowski Brenton L. Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Yehia Hashad - Executive VP of Research & Development and Chief Medical officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Joanne Wuensch - Citigroup Inc., Research Division Young Li - Jefferies LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Pito Chickering - Deutsche Bank AG, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Douglas Miehm - RBC Capital Markets, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good morning, and welcome to Bausch + Lomb's Third Quarter 2025 Earnings Call.
Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch + Lomb (BLCO) Q3 Earnings Beat Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.17 per share a year ago.
Bausch + Lomb Corporation (BLCO) Q2 2025 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Brenton L. Saunders - CEO & Chairman George Gadkowski - Corporate Participant Osama A.
Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.13 per share a year ago.
New Strong Sell Stocks for July 24th
COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.
